BioDelivery Sciences International Company Profile (NASDAQ:BDSI)

BioDelivery Sciences International trades on the NASDAQ under the ticker symbol "BDSI."

BioDelivery Sciences International, Inc. (NASDAQ:BDSI) released its quarterly earnings results on Monday, May, 15th. The company reported $0.58 EPS for the quarter, topping the Zacks' consensus estimate of $0.09 by $0.49. The company had revenue of $29.48 million for the quarter, compared to analyst estimates of $27.07 million. BioDelivery Sciences International had a negative return on equity of 1.45% and a negative net margin of 0.19%. View BioDelivery Sciences International's Earnings History.

BioDelivery Sciences International is scheduled to release their next quarterly earnings announcement on Monday, August, 7th 2017. View Earnings Estimates for BioDelivery Sciences International.

6 equities research analysts have issued 1-year target prices for BioDelivery Sciences International's stock. Their predictions range from $3.00 to $5.00. On average, they anticipate BioDelivery Sciences International's share price to reach $4.00 in the next year. View Analyst Ratings for BioDelivery Sciences International.

Here are some recent quotes from research analysts about BioDelivery Sciences International stock:

• 1. Cantor Fitzgerald analysts commented, "A Lot of Moving Parts and 1x Items: BDSI reported 1Q17 results posting net income of $0.89, the majority of which was attributed to positive effects of the Belbuca return. These items included $20M in deferred revenue recognition, $27M in non-cash bargain purchase gain and a $16M tax benefit. Without these additions, BDSI would have reported a loss of ($0.23). BDSI finished 1Q with $35.2M in cash, which the company estimates should fund operations into 2H18. We have adjusted our estimates to reflect quarter and year end results. Alignment of Fundamentals: We have watched the re-launch of Belbuca closely following the ENDP transition with the recently expanded sales force growing Rx numbers through 1Q and April, per Symphony data. More importantly, $/Rx continues to increase with due to larger prescriptions and incremental price increases. We also note a significant shift to commercial payor which should allow for increased gross/net adding to the top-line. The expanded sales force of 65 armed with revised marketing messaging, particularly around titration, has been targeting physicians familiar with the buprenorphine molecule with success, in our view. We believe additional education campaigns such as speaker programs and a PAINWeekEND symposium will drive interest. Additional Upside: We see additional upside as BDSI focuses on managed Medicaid contracts of which BDSI as of Feb." (5/16/2017)
• 2. FBR & Co analysts commented, "BioDelivery reported 4Q16 results after the close on March 16. On the morning of March 17, management hosted a call to provide an update on 2017 progress. The company recently announced that it has entered into a senior credit facility with affiliates of CRG LP , which is a healthcare-focused investment firm, and currently has debt financing of up to $75M secured, with initial proceeds extending the company’s cash runway into 2H18." (3/20/2017)
• 3. According to Zacks Investment Research, "BioDelivery expects Bunavail to benefit from the Health and Human Services (HHS) ruling and new contract wins. However, Belbuca’s start has been slower than expected due to pain market pressures. Moreover, the company discontinued development of clonidine topical gel for management of painful diabetic neuropathy. BioDelivery’s portfolio as well as its pipeline candidates target highly genericized, crowded and competitive markets. Its share price also underperformed Zacks classified Medical-Biomed/Genetics Market in last one year. On the flip side, since this July, the company has secured improved positioning in six new managed care contracts, providing preferred access to Bunavail, which is expected to boost the drug’s sales and profitability in 2017. Estimates have been going down lately ahead of the company’s Q4 earnings release. The company has mixed record of earnings surprises in recent quarters." (3/14/2017)

Some companies that are related to BioDelivery Sciences International include Tetraphase Pharmaceuticals (TTPH), Corium International (CORI), Neos Therapeutics (NEOS), Adamis Pharmaceuticals Corporation (ADMP), Allergy Therapeutics plc (AGY), Aralez Pharmaceuticals (ARLZ), Concordia International Corp. (CXRX), Diurnal Group PLC (DNL), Innocoll Holdings (INNL), Neuralstem (CUR), Intellipharmaceutics International (IPCI), Amryt Pharma PLC (AMYT), SCYNEXIS (SCYX), Pernix Therapeutics Holdings (PTX), Histogenics Corporation (HSGX), Evoke Pharma (EVOK), Marinus Pharmaceuticals (MRNS) and Venture Life Group PLC (VLG).

BioDelivery Sciences International's management team includes the folowing people:

• Frank E. O'Donnell Jr., M.D., Executive Chairman of the Board
• Mark A. Sirgo Pharm.D., President, Chief Executive Officer, Vice Chairman of the Board
• Ernest R. De Paolantonio CPA, Chief Financial Officer, Treasurer, Secretary
• Niraj Vasisht Ph.D., Senior Vice President of Product Development and Chief Technical Officer
• Peter L. Ginsberg, Vice President - Business Development
• William B. Stone, Lead Independent Director
• Timothy C. Tyson, Director
• Charles J. Bramlage, Independent Director
• Thomas W. D'Alonzo, Independent Director
• Barry I. Feinberg M.D., Independent Director

BioDelivery Sciences International's stock is owned by many different of institutional and retail investors. Top institutional investors include Broadfin Capital LLC (9.85%), Stonepine Capital Management LLC (5.19%), Ameriprise Financial Inc. (4.33%), Vanguard Group Inc. (4.15%), Grandeur Peak Global Advisors LLC (1.84%) and Bank of Montreal Can (1.32%). Company insiders that own BioDelivery Sciences International stock include Barry I Feinberg, Charles Bramlage, Francis E Odonnell Jr, Mark A Sirgo, Niraj Vasisht, Paolantonio Ernest Robert De, Samuel P Sears, Jr, Thomas D'alonzo and William B Stone. View Institutional Ownership Trends for BioDelivery Sciences International.

BioDelivery Sciences International's stock was sold by a variety of institutional investors in the last quarter, including Ameriprise Financial Inc., Morgan Stanley, Searle & CO., Sabby Management LLC, Janney Montgomery Scott LLC, Bank of Montreal Can and California Public Employees Retirement System. Company insiders that have sold BioDelivery Sciences International stock in the last year include Francis E Odonnell Jr, Mark A Sirgo, Niraj Vasisht, Paolantonio Ernest Robert De, Samuel P Sears, Jr and William B Stone. View Insider Buying and Selling for BioDelivery Sciences International.

BioDelivery Sciences International's stock was bought by a variety of institutional investors in the last quarter, including Hikari Power Ltd, Stonepine Capital Management LLC, Blair William & Co. IL, Renaissance Technologies LLC, KCG Holdings Inc., Grandeur Peak Global Advisors LLC, Vanguard Group Inc. and Geode Capital Management LLC. Company insiders that have bought BioDelivery Sciences International stock in the last two years include Barry I Feinberg, Charles Bramlage, Niraj Vasisht, Paolantonio Ernest Robert De and Thomas D'alonzo. View Insider Buying and Selling for BioDelivery Sciences International.

Shares of BioDelivery Sciences International can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of BioDelivery Sciences International stock can currently be purchased for approximately $2.95.